Physician

Ankoor Shah, M.D.

According to 2025 Medicare claims, Ankoor Shah, M.D. (NPI: 1306024161) practices rheumatology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is DUKE HEALTH INTEGRATED PRACTICE, INC. (NPI: 1205553369; TIN: 862109896) and primary practice location at 27710-4000. Shah is affiliated with the Duke Connected Care, LLC (ACO ID: A2419), participating under the MSSP model.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 113 traditional Medicare patients, billed 282 HCPCS/CPT codes, and received $15,316 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 976 prescription claims across 133 beneficiaries totaling $444,644 in drug costs, led by Ambrisentan (Ambrisentan). 2017 DME data shows 36 claims. Open Payments data shows 1 records totaling $16,694. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $24,437 to $15,316. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	254	508	$24,437
2016	251	763	$33,151
2017	277	724	$29,401
2018	300	670	$36,309
2019	191	366	$19,759
2020	102	156	$10,399
2021	114	167	$15,381
2022	112	153	$13,495
2023	107	149	$13,154
2024	113	282	$15,316

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	191	1,212	$392,865
2016	193	1,293	$443,304
2017	184	1,320	$375,759
2018	185	1,375	$424,966
2019	189	1,306	$312,449
2020	133	991	$245,068
2021	110	808	$375,532
2022	112	744	$425,100
2023	132	952	$440,049
2024	133	976	$444,644

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	61	$49,264
2017	N/R	36	$26,440
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	12	12	$123
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	72	99	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	28	28	$54
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	88	115	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ambrisentan	Ambrisentan	22	660	$115,295
Actemra	Tocilizumab	14	392	$58,867
Mycophenolate Mofetil	Mycophenolate Mofetil	96	4,014	$15,100
Mycophenolic Acid	Mycophenolate Sodium	26	1,200	$12,485
Tadalafil	Tadalafil	16	600	$5,770

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$16,694	Boehringer Ingelheim Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ankoor Shah, M.D.?

Tedicare shows public-source Medicare data for Ankoor Shah, M.D. (NPI 1306024161), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ankoor Shah, M.D. have ACO affiliation data?

Ankoor Shah, M.D. is shown with ACO affiliation data for Duke Connected Care, LLC (MSSP, ACO ID A2419).

What billing organization is linked to Ankoor Shah, M.D.?

Ankoor Shah, M.D. is linked to DUKE HEALTH INTEGRATED PRACTICE, INC. (billing NPI 1205553369) in the available physician profile data.

Does Ankoor Shah, M.D. have Open Payments data?

Ankoor Shah, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.